Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Acta Clin Belg ; 74(3): 200-202, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29912651

RESUMEN

BACKGROUND: Fixed drug eruptions (FDE) are characterized by recurrent, usually solitary erythematous or dark red macular, plaque or bullous lesions, all at the same site. Among the first choices for antidotal treatment in mercury exposure, 2,3-dimercapto-1-propanesulfonic acid (DMPS) is generally a drug with a low incidence of side effects. FDE due to DMPS was not detected in our literature research and so we aimed to present this rare case. CASE REPORT: Forty-eight-year-old male patient, gunpowder and explosives factory worker, was admitted to our hospital because of mercury exposure and we started DMPS treatment. On the second day of chelation treatment, swelling and felting on lips and complaints of wound formation in genital areas started. Annular, purple color plaque on penis with no angioedema was observed. Case was regarded as FDE. Systemic and topical steroid therapy was started after termination of chelation therapy and lesions regressed with steroids. DISCUSSION: Drug eruptions are substantially common dermatological problems and can be seen in about 2.2% of inpatients. The most common unexpected effects of DMPS are allergic skin reactions. The clinical state regress rapidly after the cessation of chelation therapy.


Asunto(s)
Quelantes/efectos adversos , Erupciones por Medicamentos/tratamiento farmacológico , Intoxicación por Mercurio/tratamiento farmacológico , Unitiol/efectos adversos , Quelantes/uso terapéutico , Erupciones por Medicamentos/etiología , Glucocorticoides/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Enfermedades del Pene/inducido químicamente , Enfermedades del Pene/tratamiento farmacológico , Unitiol/uso terapéutico
2.
Inflammopharmacology ; 21(6): 413-9, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23794063

RESUMEN

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most used drugs in musculoskeletal disorders, but their systemic adverse effects limit their therapeutic benefit in local inflammation. On the other hand, topical preparations of capsaicinoids are widely used for musculoskeletal disorders as a complementary therapy. In this study, the effects of both topical capsaicinoids-containing patch and local subcutaneous capsaicin application on the anti-inflammatory action of NSAID were examined. Carrageenan-induced paw oedema of rats was used as the inflammation model. The volume and weight of the paw oedema and plasma extravasation in the paw were determined after carrageenan injection. The systemic application of diclofenac (3 mg/kg), which is an NSAID, significantly decreased the volume and weight of the paw oedema. Topical capsaicinoids-containing patch application or local capsaicin injection (2, 10, 20 µg/paw) alone did not cause any effect on oedema volume and weight. However, the combination of diclofenac with topical capsaicinoids-containing patch significantly increased the effectiveness of diclofenac on inflammation. Evans blue content of the paws that represents plasma extravasation was decreased by capsaicinoids-containing patch with and without diclofenac and diclofenac combination with the lowest dose of capsaicin injection. The results of this study indicate that topical application of capsaicinoids-containing patch enhances the anti-inflammatory effect of diclofenac and its beneficial effect may not purely relate to its capsaicin content. In the treatment of local inflammatory disorders, the combination of NSAID with topical capsaicinoids-containing patch could increase the anti-inflammatory efficiency of drug without systemic side effects.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Capsaicina/análogos & derivados , Diclofenaco/uso terapéutico , Modelos Animales de Enfermedad , Edema/prevención & control , Extractos Vegetales/uso terapéutico , Fármacos del Sistema Sensorial/uso terapéutico , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/agonistas , Capsaicina/administración & dosificación , Capsaicina/efectos adversos , Capsaicina/uso terapéutico , Capsicum/química , Carragenina , Diclofenaco/administración & dosificación , Diclofenaco/efectos adversos , Diclofenaco/agonistas , Relación Dosis-Respuesta a Droga , Edema/inmunología , Femenino , Frutas/química , Interacciones de Hierba-Droga , Inyecciones Intramusculares , Inyecciones Subcutáneas , Extractos Vegetales/administración & dosificación , Extractos Vegetales/efectos adversos , Extractos Vegetales/química , Distribución Aleatoria , Ratas , Ratas Wistar , Fármacos del Sistema Sensorial/administración & dosificación , Fármacos del Sistema Sensorial/efectos adversos , Fármacos del Sistema Sensorial/química , Parche Transdérmico/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA